A phase II study to explore the efficacy and safety of dalpiciclib plus HDACi in HR+/HER2- advanced breast cancer after the failure of CDK4/6 inhibitor therapy.
Subjects voluntarily participate in this study and sign the informed consent form
aged ≥ 18 years.
ECOG PS score: 0-2 points.
Expected survival ≥ 6 months.
Previously received treatment with histone deacetylase inhibitor (HDACi);
Previously received Dalpiciclib;
MRI or lumbar puncture confirmed leptomeningeal metastasis;
Central nervous system metastasis is confirmed by imaging; The following conditions will be excluded: 1) asymptomatic brain metastases without immediate radiotherapy or surgery; 2) Previously received local treatment (radiotherapy or surgery) for brain metastases, stable for at least 4 weeks, and no symptomatic treatment (including glucocorticoids, mannitol, bevacizumab, etc.) for more than 2 weeks with clinical symptoms;